Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Army
Chinese Patent Office
Daiichi Sankyo
Fish and Richardson

Generated: April 21, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: Mylan Labs

« Back to Dashboard

Mylan Labs Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Mylan Labs Ltd lamivudine;zidovudine;efavirenz 206040 150MG;300MG;600MG TABLET;ORAL
Mylan Labs Ltd atazanavir sulfate;ritonavir;lamivudine;zidovudine 206041 300MG;100MG;150MG;300MG TABLET;ORAL
Mylan Labs minocycline hydrochloride 201467 115MG TABLET, EXTENDED RELEASE; ORAL
Mylan Labs lamivudine; zidovudine 204914 30MG; 60MG TABLET; ORAL SUSPENSION
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chinese Patent Office
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.